VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which has de-risked RPL554 significantly. This drug has been shown to have strong bronchodilatory and anti-inflammatory effects with minimal side effects. New funds will support a broad programme of Phase II trials for maintenance therapy via a nebulizer and hospital use. It will certainly attract the attention of the drug majors. Median prices paid for Phase II respiratory assets have headline valuations of $285m (£190m), equivalent to 19p per share.
20 Jun 2016
Funding secured for Phase IIb trial
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Funding secured for Phase IIb trial
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
20 Jun 2016 -
Author:
Martin Hall -
Pages:
4
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which has de-risked RPL554 significantly. This drug has been shown to have strong bronchodilatory and anti-inflammatory effects with minimal side effects. New funds will support a broad programme of Phase II trials for maintenance therapy via a nebulizer and hospital use. It will certainly attract the attention of the drug majors. Median prices paid for Phase II respiratory assets have headline valuations of $285m (£190m), equivalent to 19p per share.